Arcus Biosciences (RCUS)
(Real Time Quote from BATS)
$13.97 USD
-0.03 (-0.21%)
Updated Aug 8, 2024 12:18 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
RCUS 13.97 -0.03(-0.21%)
Will RCUS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RCUS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RCUS
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
RCUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock?
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
Other News for RCUS
Here is the next potential market catalyst
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
Sagimet Biosciences appoints Phillips, Jarrett to board of directors
RCUS Makes Bullish Cross Above Critical Moving Average
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update